Objective responses to HDAC inhibitors have been observed using SAHA in patients with lymphoma and bladder cancer (Kelly et al, 2003) or VPA in combination with all-trans retinoic acid in patients with acute leukaemia (Bug et al, 2005; Kuendgen et al, 2006). Here, HDAC9 is linked to urinary bladder cancer.